Benefit of Belantamab Mafodotin–Based Regimen Supported in Multiple ...
The phase III DREAMM-7 study showed belantamab mafodotin-blmf combined with bortezomib and dexamethasone (BVd) significantly improved progression-free survival in relapsed/refractory multiple myeloma, with a median of 36.6 months vs 13.4 months for DVd. BVd also showed a trend towards better overall survival and higher response rates, despite more serious adverse events, including ocular effects.
Reference News
The phase III DREAMM-7 study showed belantamab mafodotin-blmf combined with bortezomib and dexamethasone (BVd) significantly improved progression-free survival in relapsed/refractory multiple myeloma, with a median of 36.6 months vs 13.4 months for DVd. BVd also showed a trend towards better overall survival and higher response rates, despite more serious adverse events, including ocular effects.